Document Type : Letter to Editor


Assistant Professor, Department of Cardiology, Cardiovascular Research Center, Mazandaran University of Medical Sciences, Sari, Iran


This article does not have an abstract

  1. Agrawal S, Mehta PK, Bairey Merz CN. Cardiac Syndrome X: Update. Heart Fail Clin 2016; 12(1): 141-56.
  2. Fongemie J, Felix-Getzik E. A review of nebivolol pharmacology and clinical evidence. Drugs 2015; 75(12): 1349-71.
  3. Gao Y, Vanhoutte PM. Nebivolol: An endothelium-friendly selective beta1-adrenoceptor blocker. J Cardiovasc Pharmacol 2012; 59(1): 16-21.
  4. Sen N, Tavil Y, Erdamar H, Yazici HU, Cakir E, Akgul EO, et al. Nebivolol therapy improves endothelial function and increases exercise tolerance in patients with cardiac syndrome X. Anadolu Kardiyol Derg 2009; 9(5): 371-9.
  5. Kayaalti F, Kalay N, Basar E, Mavili E, Duran M, Ozdogru I, et al. Effects of nebivolol therapy on endothelial functions in cardiac syndrome X. Heart Vessels 2010; 25(2): 92-6.
  6. Erdamar H, Sen N, Tavil Y, Yazici HU, Turfan M, Poyraz F, et al. The effect of nebivolol treatment on oxidative stress and antioxidant status in patients with cardiac syndrome-X. Coron Artery Dis 2009; 20(3): 238-4.